Atlas Trials

Kite, A Gilead Company

36 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Kite, A Gilead Company

RecordFirmDate
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy (NCT07479797)Kite, A Gilead Company2026-05-22
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases (NCT07304154)Kite, A Gilead Company2026-04-10
A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment (NCT06539338)Kite, A Gilead Company2024-09-20
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (NCT06413498)Kite, A Gilead Company2024-08-23
Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (NCT06253663)Kite, A Gilead Company2024-03-18
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma (NCT06079164)Kite, A Gilead Company2023-11-09
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (NCT05605899)Kite, A Gilead Company2023-02-10
Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (NCT05537766)Kite, A Gilead Company2022-11-01
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (NCT05371093)Kite, A Gilead Company2022-09-22
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma (NCT05459571)Kite, A Gilead Company2022-08-09
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) (NCT05396885)Kite, A Gilead Company2022-07-15
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells (NCT05041309)Kite, A Gilead Company2021-12-15
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma (NCT04989803)Kite, A Gilead Company2021-10-27
Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (NCT04789408)Kite, A Gilead Company2021-07-19
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (NCT04880434)Kite, A Gilead Company2021-04-23
Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (NCT04314843)Kite, A Gilead Company2020-05-26
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma (NCT04155749)Kite, A Gilead Company2019-12-23
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma (NCT04002401)Kite, A Gilead Company2019-11-05
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (NCT03761056)Kite, A Gilead Company2019-01-29
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma (NCT03704298)Kite, A Gilead Company2018-11-20
Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (NCT03624036)Kite, A Gilead Company2018-11-15
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (NCT03391466)Kite, A Gilead Company2018-01-25
Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers (NCT03139370)Kite, A Gilead Company2017-12-27
Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma (NCT03318861)Kite, A Gilead Company2017-10-20

Track Kite, A Gilead Company automatically

Every clearance here is in the API, with alerts when new ones post.